Browsing by Keyword "erlotinib"

Now showing items 1-3 of 3

    • Erlotinib for Progressive Vestibular Schwannoma in Neurofibromatosis 2 Patients 

      Plotkin, Scott Randall; Halpin, Chris; McKenna, Michael; Loeffler, Jay Steven; Batchelor, Tracy Todd; Barker, Frederick George (Ovid Technologies (Wolters Kluwer Health), 2010)
      In vitro treatment of Nf2-deficient cells with epidermal growth factor receptor (EGFR) inhibitors can inhibit cellular proliferation. We retrospectively assessed the effect of erlotinib (150 mg daily) on eleven consecutive ...

    • Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer 

      Schöttle, Jakob; Chatterjee, Sampurna; Volz, Caroline; Siobal, Maike; Florin, Alexandra; Rokitta, Dennis; Hinze, Yvonne; Dietlein, Felix; Plenker, Dennis; König, Katharina; Albus, Kerstin; Heuckmann, Johannes M.; Rauh, Daniel; Franz, Thomas; Neumaier, Bernd; Fuhr, Uwe; Heukamp, Lukas C.; Ullrich, Roland T. (Impact Journals LLC, 2015)
      Treatment with EGFR kinase inhibitors improves progression-free survival of patients with EGFR-mutant lung cancer. However, all patients with initial response will eventually acquire resistance and die from tumor recurrence. ...

    • Rapidly fatal advanced EGFR -mutated lung cancers and the need for rapid tumor genotyping in clinical practice 

      Rangachari, Deepa; Drake, Lauren; Huberman, Mark S.; McDonald, Danielle C.; Vanderlaan, Paul A; Folch, Erik E; Costa, Daniel Botelho (Elsevier BV, 2016)
      Use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is associated with dramatic, durable, and tolerable responses and side effect profiles, respectively, when applied for palliation of advanced ...